| Literature DB >> 28181424 |
Peng Zhao1, David O Nettleton2, Rajeshri G Karki2, Frédéric J Zécri2, Shih-Yuan Liu1.
Abstract
The first examples of biologically active monocyclic 1,2-azaborines have been synthesized and demonstrated to exhibit not only improved in vitro aqueous solubility in comparison with their corresponding carbonaceous analogues, but in the context of a CDK2 inhibitor, also improved biological activity and better in vivo oral bioavailability. This proof-of-concept study establishes the viability of monocyclic 1,2-azaborines as a novel pharmacophore with distinct pharmacological profiles that can help address challenges associated with solubility in drug development research.Entities:
Keywords: BN heterocycle; CDK2 inhibitors; azaborines; drug discovery; solubility
Mesh:
Substances:
Year: 2017 PMID: 28181424 PMCID: PMC5654323 DOI: 10.1002/cmdc.201700047
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466